Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers

Area of Science:

• Oncology
• Genetics
• Gynecology

Background:

• Bilateral risk-reducing oophorectomy (BRRO) is a key strategy for managing hereditary cancer risk in BRCA1/2 mutation carriers.
• BRRO offers substantial reductions in breast and ovarian cancer incidence but can lead to premature menopause and associated symptoms.
• The decision-making process for BRRO involves complex considerations, including surgical timing, hysterectomy, and hormone replacement therapy (HRT).

Purpose of the Study:

• To review the current evidence on BRRO in BRCA1/2 mutation carriers.
• To specifically examine the role and impact of HRT following BRRO in this population.
• To inform clinical practice regarding individualized patient management.

Main Methods:

• Literature review of studies on BRRO and HRT in BRCA1/2 mutation carriers.
• Analysis of data concerning cancer risk reduction, menopausal symptoms, quality of life, and bone health.
• Focus on recent findings regarding the interaction between HRT and BRRO's efficacy.

Main Results:

• BRRO significantly reduces breast cancer risk by ~50% and ovarian cancer risk by 85-95%.
• Potential adverse effects include menopausal symptoms, reduced quality of life, and accelerated bone loss.
• Recent data indicate HRT does not negate the breast cancer risk reduction achieved by BRRO in unaffected premenopausal women.

Conclusions:

• BRRO is an effective risk-reducing procedure for BRCA1/2 carriers, but requires individualized management.
• The use of HRT after BRRO should be carefully considered, balancing symptom management with oncologic safety.
• Current evidence supports the use of HRT in select cases without compromising the primary cancer risk reduction benefits of BRRO.